Adalimumab in active ulcerative colitis: A "real-life" observational study

Digestive and Liver Disease

Volumn 45, Issue 9, 2013, Pages 738-743

  Armuzzi, Alessandro ^a   Biancone, Livia ^b   Daperno, Marco ^c   Coli, Alessandra ^d   Pugliese, Daniela ^a   Annese, Vito ^e   Aratari, Annalisa ^f   Ardizzone, Sandro ^g   Balestrieri, Paola ^h   Bossa, Fabrizio ⁱ   Cappello, Maria ^j   Castiglione, Fabiana ^k   Cicala, Michele ^h   Danese, Silvio ^l   D'Incà, Renata ^m   Dulbecco, Pietro ⁿ   Feliciangeli, Giuseppe ^o   Fries, Walter ^p   Genise, Stefania ^e   Gionchetti, Paolo ^q   Gozzi, Stefano ^r   Kohn, Anna ^s   Lorenzetti, Roberto ^h   Milla, Monica ^e   Onali, Sara ^b   Orlando, Ambrogio ^j   Giovanni Papparella, Luigi ^s   Renna, Sara ^j   Ricci, Chiara ^t   Rizzello, Fernando ^q   Sostegni, Raffaello ^c   Guidi, Luisa ^a   Papi, Claudio ^f   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f SAN FILIPPO NERI HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j UNIVERSITY OF PALERMO   (Italy)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^l HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o Macerata Hospital   (Italy)

^p UNIVERSITY OF MESSINA   (Italy)

^q UNIVERSITY OF BOLOGNA   (Italy)

^r IRCCS POLICLINICO SAN DONATO   (Italy)

^s SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^t UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

"Real life" study; Adalimumab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; STEROID;

ADULT; ARTICLE; COHORT ANALYSIS; COLON RESECTION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; REMISSION; RETROSPECTIVE STUDY; ULCERATIVE COLITIS;

" REAL-LIFE" STUDY; ADALIMUMAB; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84876046983     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.03.018     Document Type: Article

References (27)

1. Edwards F.C., Truelove S.C. The course and prognosis of ulcerative colitis. Gut 1963, 4:299-315.
2. Ng S.C., Kamm M.A. Therapeutic strategies for the management of ulcerative colitis. Inflammatory Bowel Diseases 2009, 15:935-950.
3. Danese S., Fiocchi C. Ulcerative colitis. New England Journal of Medicine 2011, 365:1713-1725.
4. Rutgeerts P., Sandborn W.J., Feagan B., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 233:2462-2473.
5. Järnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
6. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
7. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
8. Ferrante M., Vermeire S., Fidder H., et al. Long-term outcome after infliximab for refractory ulcerative colitis. Journal of Crohn's and Colitis 2008, 2:219-225.
9. Orlando A., Armuzzi A., Papi C., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2011, 43:1-20.
10. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clinical Gastroenterology and Hepatology 2004, 2:542-553.
11. HUMIRA® Product Monograph. Abbott.
12. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
13. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
14. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Annals of Internal Medicine 2007, 146:829-838.
15. Panaccione R., Colombel J.F., Sandborn W.J., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics 2010, 31:1296-1309.
16. Oussalah A., Laclotte C., Chevaux J.B., et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Alimentary Pharmacology and Therapeutics 2008, 28:966-972.
17. Afif W., Leighton J.A., Hanauer S.B., et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflammatory Bowel Diseases 2009, 15:1302-1307.
18. Gies N., Kroeker K.I., Wong K., et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Alimentary Pharmacology and Therapeutics 2010, 32:522-528.
19. Taxonera C., Estellés J., Blanco I., et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Alimentary Pharmacology and Therapeutics 2011, 33:340-348.
20. Ferrante M., Karmiris K., Compernolle G., et al. Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome. Gut 2011, 60(Suppl. 3):A72.
21. McDermott E., Murphy S., Keegan D., et al. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. Journal of Crohn's and Colitis 2013, 7:150-153.
22. Reinisch W., Sandborn W.J., Hommes D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
23. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
24. Dignass A., Eliakim R., Magro F., et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definition and diagnosis. Journal of Crohn's and Colitis 2012, 6:965-990.
25. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology 2005, 19(Suppl. A):5-36.
26. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine 1987, 317:1625-1629.
27. Armuzzi A., Pugliese D., Danese S., et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflammatory Bowel Disease 2013, 19:1065-1072.